Revised guidelines for good practice in IVF laboratories

M. Cristina Magli, Etienne Van den Abbeel*, Kersti Lundin, Dominique Royere, Josiane Van der Elst and Luca Gianaroli for Committee of the Special Interest Group on Embryology

Laarbeeklaan 101, Brussels 1090, Belgium

*Correspondence address. UZ Brussel, Centre for Reproductive Medicine, Laarbeeklaan 101, 1090 Brussels, Belgium. E-mail: etienne.vandenabbeel@uzbrussel.be

The ‘ESHRE Guidelines for Good Practice in IVF Laboratories’ were drawn up by the Special Interest Group (SIG) in Embryology and published in the year 2000, and since then they constitute the minimal requirements for any laboratory offering assisted reproduction techniques (ART). In the understanding that the embryologist has a responsibility for the correct and justified application of ART in the laboratory, the implementation of these guidelines requires a quality management programme to be in place that encompasses and integrates the operative units, the processes and procedures that represent the core of ART clinics.

In March 2004, the European Parliament issued the Directive 2004/23/EC ‘On setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells’. The Directive applies to human tissues and cells, including fresh or frozen reproductive cells for application to the human body, and is mainly concerned with increasing quality and safety through the implementation of a quality management system.

Therefore, the European Society of Human Reproduction and Embryology (ESHRE) undertook a series of initiatives aiming to promote assurance of good laboratory practice and to define the concept of qualified embryologists. One ESHRE initiative was to revise the guidelines for good practice in IVF laboratories, not only in response to the need of embryologists for support and guidance in their duties, but also as a complement to the requirements issued by the Tissue and Cell Directive.

The SIG in Embryology hopes that this document may assist the laboratory staff to operate according to the requirements of harmonization, implementation, inspection and certification that are now common to all European member states.

Keywords: assisted reproduction techniques; European Union Tissue and Cell Directive; laboratory safety; quality assurance; quality control

Introductory remarks

In the year 2000, the European Society of Human Reproduction and Embryology (ESHRE) introduced guidelines constituting the minimal requirements for any laboratory offering assisted reproduction techniques (ART). This was done with the aim of implementing a quality system for all embryologists and IVF laboratory personnel, in the understanding that the embryologist has a responsibility for the correct and justified application of ART in the laboratory. The strict application and further development of these guidelines benefit all patients attending ART clinics, ART professionals and the embryologists themselves.

The implementation of guidelines for good practice in IVF laboratories requires a quality management programme to be in place, integrating quality control, quality assurance and quality improvement. This should be done by the design of a quality policy and a consequent implementation of a quality system that encompasses and integrates the operative units, the processes and procedures that represent the core of ART clinics.

Within this framework of quality assurance, ESHRE, in collaboration with several national embryology societies, has set up a programme for Certification of Clinical Embryologists in order to contribute to the assurance of good laboratory practice and to define the concept of qualified embryologists.

In March 2004, the European Parliament issued the Directive 2004/23/EC ‘On setting standards of quality and safety for the donation, procurement, testing, processing,
preservation, storage, and distribution of human tissues and cells’ (European Union, 2004). The Directive applies to human tissues and cells, including fresh or frozen reproductive cells for application to the human body (see Directive 2004/23/EC, p. L102/48 (7) and Article 1, Objective, p. L 102/51).

The Directive requires specifically that tissue establishments have a comprehensive quality management system. The requirements specified by the Directive and the annexed documents (Commission Directives) in which the corresponding technical directives are listed in detail, have to be applied by the Member States by the dates established in the Documents and in the respect of National regulations. The first Commission Directive ‘On the donation, procurement and testing of human tissues and cells’ has been published on 8 February 2006 (European Union, 2006), and must be implemented by member states by 1 November 2006. The second Commission Directive ‘On technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells’ was adopted on the 24th of October 2006 (European Union, 2006), and must be implemented by member states by 1 November 2006. The third Directive Directive requires specifically that tissue establishments have a comprehensive quality management system. The requirements specified by the Directive and the annexed documents (Commission Directives) in which the corresponding technical directives are listed in detail, have to be applied by the Member States by the dates established in the Documents and in the respect of National regulations. The first Commission Directive ‘On the donation, procurement and testing of human tissues and cells’ has been published on 8 February 2006 (European Union, 2006), and must be implemented by member states by 1 November 2006. The second Commission Directive ‘On technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells’ was adopted on the 24th of October 2006 (European Union, 2006), and must be implemented by member states by 1 November 2006. The third Directive.

The directives can be found at: http://ec.europa.eu/health/ph_threats/human_substance/legal_tissues_cells_en.htm

In view of these considerations, the guidelines for good practice in IVF laboratories issued by ESHRE not only respond to the need of embryologists for support and guidance in their duties, but may represent a point of reference for the national competent authorities inspecting according to the Directive.

The current version of the ‘Guidelines for good practice in IVF laboratories’ is based on the previous document (Gianaroli et al., 2000) and should be seen as a complement to the requirements issued by the Tissue Directive.

1. **Staffing and direction**

1.1 The laboratory should be directed by an appropriately qualified and experienced responsible person with qualifications of diploma and expertise in the field of embryology and biological or medical sciences according to national rules.

1.2 The responsibilities of the laboratory director should include:

1.2.1 Ensuring that laboratory facilities are appropriate and safe by systematically controlling their functioning and programming periodical maintenance.

1.2.2 Ensuring that written procedure manuals for all procedures exist and are carried out appropriately by the laboratory staff.

1.2.3 To periodically review and update procedure manuals, and ensure that only the updated version of the manual is available in the laboratory.

1.2.4 To verify that all the processes are performed in compliance with a quality system.

1.2.5 To ensure that appropriate numbers of staff are in place, having the required experience to undertake the workload of the laboratory in relation to the techniques offered.

1.2.6 To ensure that all new staff are given a comprehensive orientation and introduction programme. Beginners should follow a training scheme under the assistance and control of experienced embryologists and of the laboratory director.

1.2.7 To organize and control laboratory staff training and ensure that the staff receive continual scientific and medical education.

1.2.8 Ensuring that individual responsibility of each member of the staff and line of responsibilities are defined and indicated in written procedures that are known and accepted by all members of the staff.

1.2.9 Having regular exchange of information and discussion with the clinical colleagues.

2. **Policies and procedures**

2.1 All laboratory procedures must include provision for unique patient identification, and corresponding gametes, zygotes and embryos identification, while retaining patient confidentiality.

2.2 The updated version of detailed manuals for all procedures used should be available in the laboratory.

2.3 Written, signed and dated protocols should exist for every procedure that is performed in the laboratory.

2.4 There must be written procedures for dealing with and documenting incorrect or incomplete identification of specimens or documentation, as well as with any non-compliance, emergency situation or adverse event.

2.5 Laboratory and clinical results (i.e. fertilization rates, pregnancy rate etc.) should be regularly updated, summarized and discussed, and kept available to all staff. If necessary, appropriate action should be initiated.

2.6 A log book should be maintained to permit regular evaluation of the results, including the performance of each single operator.

2.7 Every communication with the other operative units (clinicians, geneticists, nurses and secretariat) should be specified by written procedures.

2.8 Taking into account the high degree of attention needed during embryologist’s or technician’s laboratory work, any communication to the laboratory, such as phone calls, should be kept to a minimum.

3. **Laboratory safety**

3.1 **Laboratory design**

The embryology laboratory must have adequate space to allow good laboratory practice and should be as close as possible to the operating room in which the clinical procedures are performed.

When commissioning the laboratory, thought should be given to the most recent developments in equipment and facilities. Attention should be given to the ergonomics of the operator: bench height, adjustable chairs, microscope eye height, efficient use of space and surfaces, sufficient air-condition with controlled humidity and temperature, all contributing to
a working environment that minimizes distraction and fatigue. Consideration should also be given to local health and safety requirements.

More specifically:

- The construction of the laboratory should ensure aseptic and optimal handling of gametes, zygotes and embryos during all phases of the treatment.
- Although no documented cases of viral cross-contamination due to air quality have been reported, high-efficiency particulate air and volatile organic compounds filtration of the air supplied to the laboratory and clinical procedure rooms should be considered to maintain clean conditions. In addition, overpressure of the laboratory could contribute to exclude contamination from external areas.
- Rooms for changing clothes should be located close to the laboratory, having hand washing facilities.
- Access to the laboratory should be limited to authorized personnel only.
- Pass-throughs for all materials and disposables coming into the laboratory are recommended.
- The location of storage areas and equipment such as incubators, centrifuges and cryo equipment should be logically planned for efficiency and safety within each working area.
- Separate office space should be provided for administrative work, such as record keeping and data entry.
- A general wet area in which washing of equipment, sterilisation, etc. is performed must be separate from the embryo laboratory. Analyses in which fixatives are applied must be performed in a separate room, preferably in a fume-hood.

3.2 Laboratory equipment

- The laboratory equipment must be adequate for laboratory work and easy to clean and to disinfect.
- Critical items of equipment, including incubators and frozen gamete, zygote and embryo storage facilities, should be appropriately alarmed and monitored.
- An automatic emergency generator backup in the event of power failure should be in place.
- A minimum number of two incubators is recommended. Gas cylinders should be placed outside or in a separate room with an automatic backup system.
- Incubators should be frequently cleaned and sterilized.
- Records of ordinary and extraordinary maintenance on all the equipment must be documented and retained.
- Devices for the maintenance of temperature of media, gametes, zygotes and embryos during each phase of the procedure, when they are out of the incubators, should be in place (i.e. warm stages, heating blocks).
- Regular checks of functional parameters for devices used to maintain temperature and CO2 should be performed using calibrated thermometers and extra methods of CO2 analysis and/or pH measurement. Record of these measurements, as well as those shown by the digital displays of each device, must be retained.
- The instruction manual for every instrument should be available in the laboratory.
- Written instructions should be available to all members of the staff for actions to be taken in the case of equipment failure.

3.3 Infectious agents

All assisted reproductive technologies (ART) involve handling biological material, and pose a potential hazard of transmitting diseases to personnel and to other patients’ gametes, zygotes or embryos (cross-contamination). Each unit should establish procedures and policies for the safety of personnel and for preventing cross contamination, taking national and/or local safety regulations into consideration. Therefore:

- Vaccination of the personnel against Hepatitis B or other viral disease, for which the vaccine is available, is recommended.
- Screening patients and gamete donors for human immunodeficiency virus (HIV), Hepatitis B/C and other sexually transmissible diseases before processing or cryopreservation should be routinely adopted according to Commission Directive 2006/17/EC Annex III.
- As patients’ admittance to IVF treatment cycles is regulated by physicians, and although the laboratory staff should treat each sample as potentially infectious, the laboratory staff must be informed about the risks of handling infected biological material, whenever the information is available.

The treatment of patients positive for HIV or Hepatitis B/C (diagnosed as infectious after PCR control for the presence of the viral genome) should be only performed in laboratories having dedicated areas, in which the adequate safety measures are followed. Alternatively, patients with positivity for HIV or Hepatitis B/C could be allocated to specific series or time slots during the working day, which are followed by an accurate cleaning and disinfection of the laboratory.

A Class II laminar flow cabinet that protects both the operator and the specimen should be used when contaminated samples are handled.

Under these safety conditions, the occurrence of disease transmission from semen samples carriers of HIV or Hepatitis B/C to their partners are very rare (Englert et al., 2004; Sauer, 2005), whereas no cases have been reported of infections to the operators. Only one report has been published on nosocomial infection with Hepatitis C after assisted conception (Lesourd et al., 2000).

3.4 Protective measures

All body fluids (follicular fluid, semen etc.) should be treated as potentially contaminated.

The purpose of the protective measures is both to protect laboratory staff and to ensure aseptic conditions for gametes, zygotes and embryos. The procedures should deal with, but not be limited to, the following:

- Strict observation of staff hygiene regulations.
- Use of laboratory clothing.
4. Identification of patients and their gametes, zygotes and embryos

4.1 Before commencing any procedure related to a treatment cycle, the embryologist should check that the patient has signed the corresponding consent form.

4.2 The clinical and serological exams undergone by the patients before being admitted to IVF treatment should be checked in order to detect any possible positivity to viral infections.

4.3 Written procedures should be present describing in detail the various phases of IVF techniques, including all the laboratory operative procedures, in which the protocols, the equipment and the material list should be specified. In this way, reproducibility and competence in handling gametes, zygotes and embryos can be assured.

4.4 Rules concerning the correct handling and identification of gametes, zygotes and embryo samples should be established by a system of checks and, where needed, double-checks by a second person.

- All material obtained from the patients, i.e. tubes with blood, follicular fluid and sperm samples, must bear unique identification of the treated couple.
- Incubators should be organized in order to facilitate identification of embryos, zygotes, oocytes and sperm.
- Verification of patients' identity should be performed at critical steps: before ovum pickup, at semen recovery, at insemination or ICSI, at cryopreservation and at embryo transfer procedures.
- Double checks are recommended at least at: insemination of oocytes, replacement of embryos, zygote or embryo freezing and thawing.
- Documentation of all critical steps in each patient's file is essential.
- The identity of the laboratory person handling the samples at each point of the process, from receipt through final disposition, date and time, should be clearly indicated. This permits tracking of the sample throughout its period in the laboratory, also at later dates.

4.5 Proper training of all the laboratory staff accordingly to these procedures is mandatory.

5. Culture media preparation and quality control testing


5.1 Reagents

- Culture media should be of tissue culture grade, preferably mouse embryo tested and with purity appropriate for the purpose. Use of commercially produced, quality controlled tested media is recommended. When commercially produced media are used, it is important to check that producers use validated quality control testing, if not this has to be done by the laboratory. In addition, integrity of the packages and appropriate delivery conditions should be controlled. Documentation of quality control testing using an adequate bioassay system must be supplied by the manufacturer for any commercially produced media employed. Correspondence with the delivered batch should be verified.
• Reagents and media should always be used prior to the manufacturer’s expiry date.
• Appropriate refrigeration facilities must be available for media and reagents storage.

5.2 Donor serum or follicular fluid is not recommended as medium additives.
Commercial suppliers of human serum albumin or media containing a serum derived protein source should supply evidence of screening according to the local rules for blood donors.

5.3 Use of mineral oil.
Oocytes, zygotes and embryos may be cultured under equilibrated mineral oil. The oil aids in maintaining temperature, osmotic pressure and pH during short-term manipulations of the oocytes.
Similarly to commercially produced media, documentation of quality control testing including an adequate bioassay system should be supplied by the manufacturer.

5.4 Each lot of culture media and mineral oil should be recorded in each patient’s worksheet, or alternatively, documented during which exact period of time it has been used, thereby being traceable for each step of the procedure for each patient.

6. Handling of embryos, zygotes, oocytes and spermatozoa
The laboratory procedures regarding the handling of embryos, zygotes and gametes for ART have been standardized. The procedures should be easy, simple and effective and should be performed in a laminar flow hood equipped with heating stages and pre-warmed heating blocks. Class II hoods should be used for documented contaminated samples, since they provide protection also to the operator. Aseptic technique should be used at all times.

6.1 Appropriate measures should be taken to ensure that oocytes, zygotes and embryos are maintained at 37°C during handling/observation.

6.2 Whenever possible, tissue culture grade disposables should be used for handling body fluids/cells (see Commission Directive 2006/17/ p. L 38/50 on medical devices, and Commission Directive 2006/86/ p. L 294/34 and L 294/38, C.6 on critical reagents and materials). Record of lot numbers used for each period of time should be documented and kept.

6.3 Pipetting devices (pasteurs, drawn pipettes, tips etc.) should be used for one procedure only, must never be used for more than one patient, and should be disposed of immediately after use.

6.4 Simultaneous treatment of more than one patient should never be done in the same working place. Each sample should be handled individually and its treatment should be completed before moving to the following sample.

6.5 Identifying information marked on the culture dish/tube should be cross referenced to the patient and the patient’s documentation.
• Procedures must be in place, which ensure correct patient identification at all stages.

6.6 At each stage of the procedure, date, time and identity of the operator should be recorded. This is especially useful in cases of recalls.

6.7 Before receiving samples, the identity of the corresponding patients should be confirmed.

6.8 All the above points are also to be applied during freezing and to thawed gametes, zygotes and embryos with the exception of temperature requirement during thawing that may vary according to the used protocol.

7. Oocyte retrieval
As the meiotic spindle starts to depolymerize at about 35°C, oocytes need to be kept at body temperature (close to 37°C) as much as possible. Following temperature-induced depolymerization, the spindle reassembles spontaneously when the temperature rises again, but errors in this process may cause aneuploidy (Pickering et al., 1990).

7.1 There should be appropriate equipment in use to maintain a 37°C temperature, also when laboratory and egg collection areas are on different sites. Petri dishes for scanning oocytes, collection tubes and heating blocks should be pre-warmed at 37°C.

7.2 Detailed written procedures for oocyte collection and culture must be available.

7.3 Follicular aspirates are checked for the presence of oocyte-cumulus complexes under a stereo dissecting microscope with transmitted illumination base and heated stage, usually at 8-60x magnification. Exposure of oocytes to light should be minimized.

7.4 Morphological criteria for the description of oocyte quality and maturity, as well as modality of observation should be specified. The morphological evaluation of the recovered oocytes should be documented in the patient’s worksheet.

7.5 Where donor oocytes are to be used, traceability must be guaranteed according to the rules existing in the clinic. Whenever freezing donor oocytes, the unique European code must be used. The implementation of this unique code is foreseen for the end of 2008.

8. Sperm preparation
Before starting a treatment cycle, semen analysis should be performed according to the protocols described in the World Health Organization (WHO) manual (WHO, 1999 or updated edition). Patients should be given clear and precise instructions regarding the collection of the sperm sample.

8.1 The semen sample is collected in a sterile, plastic container (tissue grade, if available) without using spermicidal condoms, creams or lubricants. The container should be clearly labelled with the names of the couple. An identification procedure must be in place to allow allocation of a sperm sample to a patient,
especially in cases of samples produced outside clinic facilities. After collection, the sample should be delivered to the laboratory as soon as possible, preferably within one hour from collection, and extreme temperatures should be avoided (WHO, 1999).

8.2 Records should be kept of the type of container used (if this differs from the norm), time and place of collection (with particular reference to samples produced outside clinic facilities), and the time interval between collection and preparation.

8.3 Where donor sperm is used, the necessary identifying information (donor code/clinic code) must be recorded. The definition of a unique European code is foreseen for the end of 2007 with implementation in 2008. From then, the unique European code must be used.

8.4 Written procedures should be available and include:
- medium type
- sperm preparation technique (e.g. swim-up or gradient centrifugation procedure)
- semen to medium ratio
- centrifugation time and force
- incubation time and condition

8.5 The method of sperm preparation should be recorded, including details of any variation on the standard laboratory protocol.

8.6 A record should be kept of pre- and post- preparation sperm parameters and of any dilution carried out prior to insemination.

8.7 In case of surgically retrieved spermatozoa, surplus sperm after insemination should be cryopreserved for further assisted reproductive cycles; this will avoid repeated surgery.

8.8 Sperm preparations must also be protected from extreme temperature (Mortimer, 2005):
- If the sperm suspension cools down below 20°C, cold-shock occurs due to changes in the membrane phospholipids phase behaviour.
- If the temperature rises above the physiological norm, spermatozoa will be irreversibly damaged.

8.9 Preparation of spermatozoa for insemination.

8.9.1 The method of preparation is chosen according to individual samples. A trial preparation prior to the treatment cycle may be advisable in order to choose the most adequate technique. Sperm preparation is aimed to:
- concentrate and select the active and motile spermatozoa;
- discard seminal plasma, debris and contaminants;
- select against abnormal forms.

8.9.2 A frozen backup sample may be requested for those patients for which the possibility of sperm collection difficulty is anticipated.

8.9.3 Different methods are used for sperm preparation. Among them, the swim-up technique and the discontinuous density-gradient centrifugation are the most used. The standard protocols for sperm preparation must be detailed in a written procedure. As a general rule, excessive centrifugation should be avoided especially in oligospermic samples in order to avoid increasing the concentration of reactive oxygen species (Twigg et al., 1998).

8.9.4 The culture media used for the sperm suspension are bicarbonate-buffered and therefore susceptible to pH shifts if exposed to atmospheric air for more than two minutes (Mortimer and Mortimer, 2005). In addition, prolonged exposure to high-velocity air flow will provoke a decrease in the suspension temperature. Hence, the procedure of sperm preparation for insemination must be performed under conditions that maximize the control of temperature and pH. After preparation, the sperm suspension should be placed at 37°C and at the right pH for optimal capacitation to occur.

9. Insemination of oocytes

9.1 Conventional IVF insemination.

9.1.1 A record should be kept of the time of insemination and the sperm concentration used.

9.1.2 The number of spermatozoa must be sufficient to yield oocyte fertilization without compromising embryo development.

9.1.3 A double identity check at the time of insemination procedure is recommended.

9.2 ICSI procedure.

9.2.1 Preparation of oocytes for ICSI. Removal of cumulus–corona cells. Oocytes are denuded from the surrounding cumulus and corona cells using an enzymatic procedure with hyaluronidase, mostly followed by mechanical denudation using a pipette. Both the enzyme concentration and the duration of exposure to the enzyme should be limited. Care needs to be taken in order to avoid damage to the oocytes, which can result from too vigorous pipetting or from a pipette diameter which is too small.

9.2.2 The injection procedure.

Record should be kept of the time of insemination (start and end of the procedure), as it depends on crucial factors such as the quality of the sperm sample and the experience of the operator. During ICSI, the following points are important:
- Morphology and maturity status of each oocyte should be recorded.
- The selection and immobilization of a viable oocyte.
- The rupture of the oolemma prior to the release of the sperm cell into the oocyte.

Viscous substances such as polyvinylpyrrolidone can be used to facilitate the manipulation of spermatozoa and to control the fluid in the injection pipette, limiting the volume injected into the oocyte.

It is important to select vital spermatozoa, as evaluated by their motility. In case of only immotile sperm cells, a vitality test can be used to select vital spermatozoa at the time of
injection. Where only non vital sperm cells are present in the ejaculate, the use of testicular sperm may be tried.

Oocytes that are immature at oocyte retrieval after conventional hormonal stimulation are known to have a high incidence of chromosomal abnormalities and a low developmental rate (Magli et al., 2006). The use of these oocytes for IVF/ICSI should therefore be avoided.

9.2.3 At the end of the procedure, both the holding and injection needles must be discarded.

9.2.4 A double identity check at the time of ICSI dish preparation is recommended.

10. Scoring for fertilization

10.1 All oocytes that have been inseminated or microinjected should be transferred into new dishes with pre-equilibrated fresh culture medium and examined for the presence and number of pronuclei and polar bodies at 16 to 20 hours post insemination.

10.2 This examination should be done under high magnification (at least ×200), using an inverted microscope equipped with Hoffman optics or equivalent, in order to verify normal fertilization and pronuclear morphology.

10.3 The morphological status of each oocyte/zygote should also be recorded.

10.4 Oocytes with one pronucleus or more than two pronuclei should be cultured separately from normally fertilized oocytes. Parthenogenetically activated oocytes can develop to blastocyst; if transferred, they will give false expectations of implantation. Zygotes with three pronuclei can also develop and a triploid karyotype could implant and occasionally reach term and delivery but the newborns die early postnatal. In addition, human triploids originated from polyspermic fertilization (representing by far the major cause of triploidy), often develop to partial hydatidiform moles that can lead to choriocarcinoma (Jauniaux, 1999; Zaragoza et al., 2000).

10.5 Oocytes showing no signs of fertilization at the expected time window should be maintained in culture and observed for late appearance of pronuclei extrusion of the second polar body and (or) cleavage. It is important to document deviations regarding the time of pronuclei and polar body appearance.

11. Embryo culture and transfer

Zygotes and preimplantation embryos are highly sensitive to culture stress resulting in perturbed metabolism with consequent altered cell function, energy production and gene expression (Lane and Gardner, 2005). Therefore, precautions must be taken to maintain adequate conditions of pH and temperature to protect zygote and embryo homeostasis.

11.1 The scoring of embryos should be performed at high magnification (at least ×200, preferably ×400) under an inverted microscope with Hoffman optics or equivalent. The evaluation should include, but not necessarily be limited to; number of cells, percentage of fragmentation, size and cytoplasmic appearance of blastomeres, nuclear status (presence of one or several nuclei per blastomere).

11.2 The stage of embryo development at the time of transfer should be documented. Embryos can be grown to Day 5 or 6 for transfer at the blastocyst stage, usually by cultures in sequential media. Current data show that blastocyst culture and transfer can be of advantage for certain groups of patients (Blake et al., 2007; Papanikolaou et al., 2007).

11.3 In some countries the maximum number of embryos to be transferred is established by local/national legislation. It is advisable not to exceed two embryos for transfer. In cases where two or more embryos are replaced, the couple has to be extensively informed on the risks of multiple gestations. As a general recommendation, the policy of single-embryo transfer is highly recommended.

Single-embryo transfers are now mandatory in some countries and practiced to a high extent in other countries. A Cochrane Collaboration review has concluded that single-embryo transfer significantly reduces the risk of multiple pregnancies, but also decreases the chance of live birth in a fresh IVF cycle (Pandian et al., 2005). Subsequent replacement of a single frozen embryo achieves a live birth rate comparable with double embryo transfer (Pandian et al., 2005). Data from randomized controlled trials have shown similar cumulative live birth rates (including following frozen-thawed transfers) in young women between single-embryo transfer and double embryo transfer (Thurin et al. 2004; Lukassen et al., 2005).

Supernumerary zygotes or embryos may be cryopreserved, donated to research or discarded, according to their quality, to the couple’s wishes and to the national legislation.

11.4 The patient records for embryo transfer must be dated and signed, and should include details of:

- Batch number and type of media used for transfer
- Time from oocyte retrieval to transfer
- Time from oocyte insemination to transfer
- The number and developmental stage of embryos at transfer
- Fate of supernumerary embryos
- Type of catheter used for transfer
- Name of the clinician performing the transfer
- Name of the operator loading the catheter
- Notes about the clinical procedure: whether the transfer was easy, difficult, presence of blood, etc. (optional)

11.5 If the laboratory is some distance from the embryo transfer room, arrangements should be made to maintain temperature and pH whilst transporting embryos.

11.7 double identity check is recommended at the moment of loading the catheter.

11.8 Before transferring the embryos, the patients’ identity must be double checked.

12. Cryopreservation of gametes, zygotes and embryos

Cryopreservation can be performed at different stages: gametes, zygotes, embryos in early cleavage (Day 2 or Day 3), morulae (Day 4) or blastocysts (Day 5–6). Embryos displaying a high degree of fragmentation, very slow cleavage or arrested embryos should be discarded from storage procedures due to the reported low survival rates and implantation potential after thawing (Gianaroli et al., 2000).

In some countries, the application of cryopreservation procedures is regulated by law and/or by the patients’ consent.

12.1 Techniques and facilities for cryopreservation of gametes, zygotes and embryos should be available in each IVF centre with the aim of:

- cryopreserving spare embryos after transfer;
- delaying embryo transfer in a subsequent cycle if the patient is unable to undergo the procedure or is at risk of developing ovarian hyperstimulation syndrome;
- storing the zygotes or embryos generated from donated oocytes in order to allow a six-month quarantine so that the potential donors may be controlled for infectious diseases prior to embryo transfer;
- establishing a fertility reserve by storing gametes, zygotes or embryos for later use as in cases of cancer patients or in women at risk of early menopause.

If the laboratory performs cryopreservation, a system should be in place for the detection of low levels of liquid nitrogen in the tanks and for high levels of nitrogen in the air. For this reason, it is recommended to keep the nitrogen tanks in dedicated, controlled areas.

12.2 Several protocols for cryopreservation, including slow-freezing protocols and vitrification protocols have been formulated depending on the embryo development stage, type of cryoprotectant, and speed of cooling.

12.3 As detailed in section 3.4, in order to minimize any risk of transmission of infection via liquid nitrogen, gametes, zygotes and embryos should be stored in specific receptacles (i.e. straws, vials etc.) that can be sealed effectively.

- Transfer of samples to receptacles should be by a method which avoids contamination of the external surface.
- Sealing should be carefully performed before freezing.

12.4 Patients whose gametes, zygotes or embryos are being processed or are to be cryopreserved must be tested according to the regulations in the Commission Directive 2006/17/EC Annex III, i.e. for HIV 1 and 2, and for Hepatitis B and C.

- When a patient is known to be a source of infection risk, a system of separate storage must be in place.
- Patients having transfer of thawed zygotes and embryos ideally should be screened for HIV 1 and 2, Hepatitis B and C.

12.5 Documentation on stored zygotes and embryos should include:

- The method of freezing and thawing
- The type and batch number of cryoprotectant(s) used.
- The stage of embryo development.
- The number of zygotes or embryos in each straw/vial (should not exceed two).
- The number of straws/vials stored per patient.

12.6 Straws/vials containing samples must be clearly and permanently labelled with reference to patient details and their unique identification code.

12.7 All reproductive cells for application to the human body are subjected to the requirements about traceability and coding that have been established by the European Directive. These rules apply to fresh and frozen cells, but for frozen cells for non-partner donation the unique European code has to be used (still to be established by the European Commission; implementation foreseen in 2008).

12.8 Storage records should be kept in both the patient’s individual records and the storage records for individual nitrogen banks.

12.9 An annual audit of stored gametes, zygotes and embryos must be carried out, cross referencing contents with storage records.

12.10 Storage records must include precise details of the location of the vials/straws.

12.11 Documentation of thawing procedures should include morphological changes seen during thawing, number of cells, number of survived cells and the time period of culture prior to transfer.

13. Assisted hatching

This technique has been designed with the aim of helping embryo hatching and possibly implantation. However there are conflicting reports about its clinical efficacy and it should be regarded as an experimental procedure.

13.1 Three methods are being used; the mechanical technique that is partial zona dissection with glass microneedles, the chemical assisted hatching using acidic Tyrode’s and the laser-assisted hatching.

13.2 Special care should be taken to avoid damage to the embryo during the procedure.

13.3 The operator, time of performance, stage of development and method used should be documented.

14. Preimplantation genetic diagnosis

The purpose of the preimplantation genetic diagnosis (PGD) procedure is to identify embryos, generated in vitro, which carry hereditary genetic diseases or chromosomal abnormalities and exclude them from transfer. Although applied in a few centers worldwide and not allowed by law in some countries, the results obtained indicate that the procedure...
does not negatively compromise embryo development and implantation despite its invasiveness. The main advantage derived from its application is being an alternative to therapeutic abortion due to a minimized risk of transferring affected embryos.

In the year 2004, the PGD International Society (PGDIS) published guidelines for good practice in PGD (Preimplantation Genetic Diagnosis International Society, 2004). The following year, the ESHRE PGD Consortium published best practice guidelines for clinical PGD and preimplantation genetic screening (Thornhill et al., 2005).

14.1 Genetic counselling should be available to all couples known to carry a hereditary disease.

14.2 The biopsy procedure may be carried out by:
- polar body removal;
- single or double blastomere biopsy at the Day 3 stage;
- trophectoderm biopsy at the blastocyst stage.

14.3 The cells destined to genetic investigation are removed in the IVF laboratory using glass microtools on a micromanipulation set. The embryology laboratory has the responsibility of providing unique identification between biopsied polar bodies, blastomeres or trophectoderm cells and the corresponding oocyte or zygote, embryo or blastocyst, respectively, implying the implementation of single oocyte/zygote/embryo/blastoctyst culture after biopsy. All cells and embryos for genetic investigation must be individually handled, carefully identified and labelled, and tracked during the whole procedure. During these steps, double identity checks are strongly recommended.

14.4 Special care must be taken to avoid damage to the embryo during the procedure. In addition, when blastomere biopsy is performed, integrity of the removed cell is extremely important for the correctness of the genetic analysis.

14.5 The biopsy sample should be subjected to diagnostic procedures in a genetic laboratory.

14.6 Pre-implantation aneuploidy screening (AS) is performed in the same way as PGD, and is sometimes used as a complement to ordinary morphological selection of embryos for transfer. It is a method used to find the chromosomally normal embryos when there is no hereditary genetic indication. Clinical efficiency of PGD-AS in randomized studies has not been proven.

15. Quality control and quality assurance

15.1 Working in compliance with a Quality Management System is mandatory according to the European Union tissue directive. This implies:
- having validated and written procedures for each aspect of the process, including the occurrence of incidents or hazards;
- whenever possible, assuring that all media/reagents/disposables etc. are tested for quality using an appropriate assay;
- verifying conformance to the specifications;
- taking any corrective action to keep procedures under conformity;
- maintaining and calibrating equipment on a periodical basis (daily/weekly/monthly/yearly)

15.2 A systematic monitoring of the testing process can be performed under Quality Assurance, aimed at improving the entire process by identifying problems, errors or improvements that may have occurred. For this internal quality assurance, results should be evaluated on a regular basis, indicators should be objective and relevant, and adequate thresholds set up. In order to prevent bias due to patient variation, a representative number of procedures in relation to the total number of procedures performed should be selected to establish the corresponding thresholds. Critical levels of laboratory performance for each indicator should be defined.

The following indicators should be regularly reviewed, analysed and discussed:
- Numbers/rates of errors and adverse events
- Rates of normally fertilized oocytes
- Cleavage rates
- Rates of embryos of good quality
- Proportion of patients with failed fertilization
- Ongoing clinical pregnancy rates (fresh and frozen/thawed transfers)
- Multiple pregnancy rates
- Implantation rates
- Rate of survival of zygotes and embryos after thawing

For a complete evaluation of the results, this analysis should be performed in collaboration with the clinical staff. In addition, the results should be related to those reported in the specialized literature, including national data and data from the European registry collected by the European IVF-monitoring programme for ESHRE (Nyboe Andersen et al., 2007).

To complement the internal quality assessments, participation in external quality assurances programmes, either commercial, or in collaboration with other laboratories, is recommended.

Conclusions

The expansion of indications for ART has not only increased the number of patients attending IVF clinics, but also the number of techniques that are currently in use. This implies that, after 30 years of IVF, there is a diversification of techniques with a consequent customization of treatment for single categories of patients.

In IVF laboratories, the diversification of the applied procedures necessitates a major attention and concentration, a systematic check of the results obtained, and a more complex training programme. Extensive research is necessary before admitting new procedures to standard technique protocols which are routinely performed in IVF laboratories.

As future perspectives, the IVF laboratory is deeply involved in defining novel techniques to be admitted (i) as standard clinical protocols which are routinely performed to expand ART indications, such as freezing of oocytes and ovarian tissue...
and in vitro maturation of oocytes, and improving embryo implantation through a better selection of gametes, zygotes and embryos; (ii) in basic research such as the generation of embryonic stem cell lines.

All these involvements require high-laboratory standards with highly qualified personnel, as well as defined quality management systems.

The present European situation and the policy adopted by the European parliament comprise a comprehensive management system to be a standard requirement for ART clinics. In this context, the ESHRE guidelines for good practice in IVF laboratories, together with the European Tissue Directives, no longer represent an option, but a prerequisite, to operate and provide the best clinical outcome in a safe working system.

Acknowledgements

These guidelines are based on the previous document published in 2000 by the authors Luca Gianaroli, Michelle Plachot, Roelof van Kooij, Safaa Al-Hasani, Karin Dawson, Anick DeVos, M. Cristina Magli, Jacqueline Mandelbaum, Jacqueline Selva, Wouter van Inzen, who at that time were actively involved in the Special Interest Group in Embryology of ESHRE for the formulation of the guidelines for good practice in IVF laboratories. It has since then been decided that ESHRE guidelines will be periodically revised, complemented and updated by the Special Interest Group in Embryology. A special acknowledgment goes to those embryologists from the Special Interest Group in Embryology that contributed with their comments to greatly improve the present document.

References


Submitted on January 9, 2008; resubmitted on February 5, 2008; accepted on February 12, 2008.